Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Eur J Pharm Biopharm ; 177: 184-198, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35787430

RESUMEN

Vitamin B12 (cyanocobalamin) deficiency is a widespread condition because of its different aetiologies, like malabsorption syndrome or lifestyles as strict veganism that is increasing its incidence and prevalence in developed countries. It has important haematological consequences that require pharmacological treatment. Current therapy consists of oral or parenteral supplements of cyanocobalamin; however, the oral route is discarded for malabsorption syndrome patients and the parenteral route is not well accepted generally. Topical treatments have been suggested as an alternative, but the molecular weight and hydrophilicity of cyanocobalamin limits its diffusion through the skin. Lipid vesicles can allow the transdermal absorption of molecules > 500 Da. The aim of this work was to use different ultraflexible lipid vesicles (transfersomes and ethosomes) to enhance cyanocobalamin transdermal delivery. Vesicles were characterized and lyophilised for long-term stability. The ability to deliver cyanocobalamin through the skin was assessed in vitro using full-thickness porcine skin in Franz diffusion cells. As expected, the best transdermal fluxes were provided by ultraflexible vesicles, in comparison to a drug solution. Moreover, the pre-treatment of the skin with a solid microneedle array boosts the amount of drug that could potentially reach the systemic circulation.


Asunto(s)
Liposomas , Síndromes de Malabsorción , Administración Cutánea , Animales , Sistemas de Liberación de Medicamentos , Lípidos , Síndromes de Malabsorción/metabolismo , Piel/metabolismo , Absorción Cutánea , Porcinos , Vitamina B 12
2.
Planta Med ; 84(9-10): 674-683, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29642242

RESUMEN

Shikonin is the main active principle in the root of Lithospermum erythrorhizon, widely used in traditional Chinese medicine for its anti-inflammatory and wound healing properties. Recent research highlights shikonin's antitumor properties and capacity to prevent acute ulcerative colitis. The aim of the present study was to evaluate the ability of shikonin to prevent, in vivo, the early phases of colorectal cancer development, with special focus on its cytotoxic mechanism in vitro. We employed the azoxymethane/dextran sulfate sodium model of colitis in Balb/C mice. Body weight and drinking were monitored throughout the experiment, and length of colon and lesions of the colon were recorded on termination of the experiment in all of the experimental groups. Colons underwent histological evaluation and biochemical analyses [myeloperoxidase activity assay, measurement of interleukin-6, evaluation of proinflammatory enzymes (cyclooxygenase-2 and inducible nitric oxide synthase), and nuclear factor-κB activation by Western blot]. Caco-2 cells were used to evaluate, in vitro, the effect of shikonin on proliferation, cytotoxicity, cell cycle, and apoptosis. Our results reveal that shikonin significantly protected the intestinal tissue of our animals by preventing the shortening of the colorectum and ulcer formation in a dose-dependent manner. Shikonin attenuated the expression of cyclooxygenase-2 and inducible nitric oxide synthase, and myeloperoxidase activity, and inhibited the production of interleukin-6 and activation of nuclear factor-κB. It induced Bcl-2 and inhibited caspase 3. In conclusion, shikonin acts as a chemopreventive agent in the azoxymethane/dextran sulfate sodium model through inhibition of the proinflammatory milieu generated during the disease, an important risk factor in cancer development.


Asunto(s)
Antiinflamatorios/farmacología , Colitis Ulcerosa/prevención & control , Neoplasias del Colon/inmunología , Inflamación/prevención & control , Enfermedades Inflamatorias del Intestino/prevención & control , Lithospermum/química , Naftoquinonas/farmacología , Animales , Apoptosis/efectos de los fármacos , Azoximetano/efectos adversos , Células CACO-2 , Colitis Ulcerosa/inducido químicamente , Colitis Ulcerosa/inmunología , Sulfato de Dextran/efectos adversos , Modelos Animales de Enfermedad , Femenino , Humanos , Enfermedades Inflamatorias del Intestino/inmunología , Medicina Tradicional China , Ratones Endogámicos BALB C , Raíces de Plantas/química , Cicatrización de Heridas/efectos de los fármacos
3.
Planta Med ; 79(18): 1685-97, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24155261

RESUMEN

The naphthoquinone shikonin is the main active principle of Zicao, a traditional Chinese herbal medicine made from the dried root of Lithospermum erythrorhizon. Studies carried out over the past 30 years have provided a scientific basis for the use of Zicao which has been long employed in folk medicine to treat a variety of inflammatory and infectious diseases. In particular, shikonin has been shown to possess many diverse properties, including antioxidant, anti-inflammatory, antithrombotic, antimicrobial, and wound healing effects. The fact that shikonin shows so many beneficial properties has increased the interest in this molecule dramatically, especially in the past few years. The aim of this review is to provide an update of the new data published on shikonin, whose wide spectrum of pharmacological effects as well as pharmacokinetic properties and toxicity make it a highly interesting target molecule.


Asunto(s)
Antiinfecciosos/farmacología , Antiinflamatorios/farmacología , Antioxidantes/farmacología , Fibrinolíticos/farmacología , Lithospermum/química , Naftoquinonas/farmacología , Antiinfecciosos/efectos adversos , Antiinfecciosos/química , Antiinfecciosos/farmacocinética , Antiinflamatorios/efectos adversos , Antiinflamatorios/química , Antiinflamatorios/farmacocinética , Antioxidantes/efectos adversos , Antioxidantes/química , Antioxidantes/farmacocinética , Fibrinolíticos/efectos adversos , Fibrinolíticos/química , Fibrinolíticos/farmacocinética , Humanos , Medicina Tradicional China , Naftoquinonas/efectos adversos , Naftoquinonas/química , Naftoquinonas/farmacocinética , Raíces de Plantas/química , Plantas Medicinales , Cicatrización de Heridas
4.
J Ethnopharmacol ; 150(3): 925-34, 2013 Dec 12.
Artículo en Inglés | MEDLINE | ID: mdl-24140585

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Pomegranate (Punica granatum L.; Lythraceae) has traditionally been used for the treatment of various inflammatory diseases, including ulcerative colitis (UC). Because its fruits and extracts are rich in ellagitannins, which release ellagic acid when hydrolyzed, consumption of pomegranate products is currently being widely promoted for their potential health effects, including the prevention of inflammatory diseases and cancer. To evaluate the anti-inflammatory effects of ellagic acid on dextran sulfate sodium (DSS)-induced acute and chronic experimental colitis in two different strains of mice and to elucidate its possible mechanisms of action. MATERIALS AND METHODS: In the acute UC model, female Balb/C mice were treated with DSS (5%) for seven days while concomitantly receiving a dietary supplement of ellagic acid (2%). In the chronic UC model, female C57BL/6 mice received four week-long cycles of DSS (1% and 2%) interspersed with week-long recovery periods along with a diet supplemented with ellagic acid (0.5%). RESULTS: In acute model of UC, ellagic acid ameliorated disease severity slightly as observed both macroscopically and through the profile of inflammatory mediators (IL-6, TNF-α, and IFN-γ). In the chronic UC model, ellagic acid significantly inhibited the progression of the disease, reducing intestinal inflammation and decreasing histological scores. Moreover, mediators such as COX-2 and iNOS were downregulated and the signaling pathways p38 MAPK, NF-κB, and STAT3 were blocked. CONCLUSIONS: Our study reinforces the hypothetical use of ellagic acid as an anti-inflammatory complement to conventional UC treatment in chronic UC patients and could be considered in the dietary prevention of intestinal inflammation and related cancer development.


Asunto(s)
Antiinflamatorios/uso terapéutico , Colitis/tratamiento farmacológico , Ácido Elágico/uso terapéutico , Animales , Antiinflamatorios/farmacología , Colitis/inducido químicamente , Colitis/metabolismo , Colitis/patología , Colon/efectos de los fármacos , Colon/metabolismo , Colon/patología , Citocinas/metabolismo , Sulfato de Dextran , Modelos Animales de Enfermedad , Ácido Elágico/farmacología , Femenino , Proteínas I-kappa B/metabolismo , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Inhibidor NF-kappaB alfa , FN-kappa B/metabolismo , Peroxidasa/metabolismo , Factor de Transcripción STAT3/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
5.
Planta Med ; 72(6): 539-46, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16773538

RESUMEN

The effects of a supercritical CO2 (SFE) extract, a dichloromethane (DCM) extract from Isatis tinctoria leaf and the alkaloidal constituent tryptanthrin were studied in acute and subchronic experimental models of inflammation. The SFE and DCM extracts showed anti-inflammatory activity in the carrageenan-induced acute mouse paw oedema (ED50 values of 78 mg/kg and 165 mg/kg P. O., respectively) and in the acute tetradecanoylphorbol acetate (TPA)-induced mouse ear oedema in oral (62% and 32% oedema reduction at 100 and 125 mg/kg, respectively) and topical application (37% and 33% reduction of oedema at 0.5 mg/ear). In contrast, tryptanthrin showed no significant anti-inflammatory effect. The DCM extract inhibited oedema formation and neutrophil infiltration in subchronic inflammation in mice induced by repeated application of TPA. The extract showed activity after oral and topical administration by reducing the various parameters of the inflammatory response. The DCM extract (1 mg/ear) inhibited the delayed-type hypersensitivity (DTH) reaction induced by application of dinitrofluorobenzene (DNFB) after topical application. The response during the induction phase (24 h) was decreased by 48%, and the inflammatory phase (48 to 96 h) was reduced by 53 to 56%. The extract had no effect in this model when administered orally. The DCM extract (200 mg/kg P. O.) inhibited the acetic acid-induced writhing by 49%.


Asunto(s)
Antiinflamatorios/farmacología , Edema/tratamiento farmacológico , Isatis , Fitoterapia , Extractos Vegetales/farmacología , Quinazolinas/farmacología , Administración Cutánea , Administración Oral , Animales , Antialérgicos/administración & dosificación , Antialérgicos/farmacología , Antialérgicos/uso terapéutico , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Carragenina , Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos Herbarios Chinos/farmacología , Medicamentos Herbarios Chinos/uso terapéutico , Edema/inducido químicamente , Femenino , Hipersensibilidad/tratamiento farmacológico , Hipersensibilidad/etiología , Ratones , Extractos Vegetales/administración & dosificación , Extractos Vegetales/uso terapéutico , Hojas de la Planta , Quinazolinas/administración & dosificación , Quinazolinas/uso terapéutico , Acetato de Tetradecanoilforbol
6.
Planta Med ; 72(8): 715-20, 2006 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16739068

RESUMEN

A dichloromethane extract of Isatis tinctoria was tested in the adjuvant-induced arthritis model in rats. The extract (150 mg/kg p. o.) leads to a significant reduction of paw oedema. Radiographic, histological and clinical assessment confirmed reduced damage of cartilage and signs of inflammatory response in comparison to untreated control. No significant differences were observed in the tissular levels of cyclooxygenases 1 and -2, and of inducible nitric oxide synthase in Isatis treated and untreated animals. High dose treatment with Isatis extract for two weeks did not result in macroscopic lesions of the gastric mucosa.


Asunto(s)
Antiinflamatorios/farmacología , Edema/prevención & control , Isatis , Fitoterapia , Extractos Vegetales/farmacología , Administración Oral , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Artritis Reumatoide/diagnóstico por imagen , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/patología , Relación Dosis-Respuesta a Droga , Edema/inducido químicamente , Femenino , Macrófagos/efectos de los fármacos , Ratones , Extractos Vegetales/administración & dosificación , Extractos Vegetales/uso terapéutico , Radiografía , Ratas , Ratas Endogámicas Lew
7.
Eur J Pharmacol ; 532(1-2): 145-54, 2006 Feb 17.
Artículo en Inglés | MEDLINE | ID: mdl-16443215

RESUMEN

23,24-Dihydrocucurbitacin B, from the anti-rheumatic plant Cayaponia tayuya, was tested on arthritis induced by adjuvant to corroborate the anti-inflammatory properties of this plant. Arthritis was induced in Lewis rats; the resulting arthritic rats were then treated with dihydrocucurbitacin B (1 mg/kg orally, daily, 1 week). The effect of dihydrocucurbitacin B on the synthesis, release, and activity of pro-inflammatory enzymes (elastase, cyclooxygenase-2, and nitric oxide synthase-2) as well as its effect on different mediators (tumor necrosis factor-alpha and interleukin-1beta) were determined. Dihydrocucurbitacin B modified the evolution of the clinical symptoms, reducing the swelling and bone and tissue damage along with the development of the disease, modifying the cell infiltration and the expression of both nitric oxide synthase-2 and cyclooxygenase-2. In addition, it decreased the tumor necrosis factor-alpha and interleukin-1beta production in lymphocytes, but did not modify it in macrophages.


Asunto(s)
Artritis Experimental/prevención & control , Cucurbitaceae/química , Triterpenos/uso terapéutico , Administración Oral , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Antirreumáticos/administración & dosificación , Antirreumáticos/aislamiento & purificación , Antirreumáticos/uso terapéutico , Artritis Experimental/metabolismo , Artritis Experimental/patología , Línea Celular , Supervivencia Celular/efectos de los fármacos , Ciclooxigenasa 2/metabolismo , Citocinas/metabolismo , Dinoprostona/metabolismo , Relación Dosis-Respuesta a Droga , Activación Enzimática/efectos de los fármacos , Femenino , Linfocitos/citología , Linfocitos/efectos de los fármacos , Linfocitos/metabolismo , Macrófagos/citología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Óxido Nítrico Sintasa de Tipo II/metabolismo , Nitritos/metabolismo , Dolor/prevención & control , Elastasa Pancreática/metabolismo , Fitoterapia , Extractos Vegetales/administración & dosificación , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/uso terapéutico , Raíces de Plantas/química , Ratas , Ratas Endogámicas Lew , Superóxidos/metabolismo , Triterpenos/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA